New combo therapy aims to keep myeloma at bay after transplant
NCT ID NCT02420860
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 36 times
Summary
This phase II trial is testing whether adding elotuzumab to standard lenalidomide maintenance therapy can help keep multiple myeloma from returning after a stem cell transplant. About 113 patients who have already had a transplant using their own stem cells will receive the combination. The goal is to see if this approach improves the time patients stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elotuzumab (a monoclonal antibody) and lenalidomide (a drug that helps the immune system fight cancer)
What this could lead to
If this works, it could offer a more effective maintenance therapy to delay or prevent multiple myeloma from coming back after a stem cell transplant.
What could go wrong
This is a mid-stage trial with only 113 participants, so results may not apply to everyone. Adding elotuzumab could increase side effects, and it's not yet proven to be better than lenalidomide alone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.